Hummingbird Bioscience discovers and engineers precision therapeutics using a proprietary Rational Antibody Discovery platform to target optimal yet elusive epitopes. The company is advancing a pipeline of first- and best-in-class therapies in oncology and autoimmunity, including clinical-stage assets. Lead programs include HMBD-001, a HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti‑VISTA neutralizing antibody for advanced solid tumors. The company is also progressing HMBD-009, a BCMA‑TACI dual‑specific T cell engager, as part of its next‑generation pipeline. Hummingbird collaborates with global partners in academia and industry to advance its programs. Piers Ingram is CEO and co-founder. Hummingbird Bioscience is a biotherapeutics company developing antibody-based treatments for cancer and other diseases. The company has published data on two oncology antibodies and expects to submit regulatory filings to start Phase 1 studies in the second half of this year. It said the new funding will be used to accelerate those therapies into clinical trials and to expand research and development for its early-stage pipeline. Hummingbird has offices in Singapore, Houston and South San Francisco and strategic collaborations with Cancer Research UK and Amgen. It was previously awarded a product development grant from the Cancer Prevention and Research Institute of Texas. Financially, the company has now raised $65 million in total, with the Series B reaching $25 million after the recent extension. Hummingbird Bioscience is a biotherapeutics company developing precision antibody therapeutics using a proprietary rational antibody discovery platform and systems biology expertise. It is building a broad pipeline of first- and best-in-class drug candidates across multiple indications, including HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA) for cancer. The company raised US$19M in a Series B and intends to use the funds to discover new disease targets, expand its antibody pipeline, and accelerate co-discovery projects under a multi-target collaboration with Amgen. HMBD-001 and HMBD-002 are expected to enter first-in-human clinical trials following regulatory submissions in the second half of 2020. The Series B was co-led by Mirae Asset Venture Investment and GNTech Venture Capital, with participation from existing investors Heritas Capital and Seeds Capital and new investors including Delian Capital, Mirae Asset Capital, DAValue-GiltEdge, HB Investment, Wooshin Venture Investment, and Kiwoom Investment-Shinhan Capital. Led by CEO and co-founder Dr. Piers Ingram, the company has strategic collaborations with Cancer Research UK and Amgen and is based in Singapore, Houston (Texas) and South San Francisco (California).

Total raised

$150M

Funding rounds

3

Latest round

Series C

Latest activity

May 2021